CellCentric
Healthcare
HQ: Cambridge, United Kingdom
Investors: 1
CellCentric is a clinical-stage biotechnology company developing novel cancer drugs, specifically focusing on p300/CBP inhibition for the treatment of prostate cancer and other hematological malignancies.
Investors (1)
| Fund | Status | Entry Date | Stage | Source |
|---|---|---|---|---|
| Sofinnova Partners | Current | - | - | Website |
Get these signals delivered weekly
Deals, exits, fundraises, and key hires from funds active in Italy — straight to your inbox.
Get Signals